{"id":"W2573557015","doi":"10.1182/blood.v126.23.1853.1853","title":"Investigating Efficacy, Safety, and Biomarkers in a Phase 2 Trial of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Following Second-Line Lenalidomide-Based Therapy (Tx) in Relapsed or Refractory Multiple Myeloma (RRMM)","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; McGill University; Vancouver General Hospital","funders":"","keywords":"Medicine; Pomalidomide; Lenalidomide; Internal medicine; Tolerability; Population; Neutropenia; Clinical endpoint; Discontinuation; Progressive disease; Oncology; Phases of clinical research; Multiple myeloma; Surgery; Adverse effect; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002794184,0.001066728,0.001323116,0.0003304878,0.0003639122,0.001069896,0.0007199504,0.00108913,0.004681725],"category_scores_gemma":[0.001572998,0.0005663669,0.001165025,0.0003237771,0.0006919542,0.0009517962,0.0005155331,0.002718186,0.0008326767],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001185462,"about_ca_system_score_gemma":0.001562052,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004536622,"about_ca_topic_score_gemma":0.001190624,"domain_scores_codex":[0.9991108,0.0004651858,0.00005019936,0.000159033,0.00008661899,0.0001282568],"domain_scores_gemma":[0.9990652,0.0001298826,0.0002865864,0.00009054907,0.00006523883,0.0003625882],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8392773,0.06536105,0.01380194,0.0004609677,0.001081781,0.0001629954,0.0002304885,0.001542114,0.02165843,0.0002145453,0.001909876,0.05429859],"study_design_scores_gemma":[0.2802384,0.6930405,0.01868508,0.00003335973,0.0006389146,0.0001711473,0.00007446243,0.001013551,0.003450937,0.0002503896,0.002376822,0.0000263309],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940982,0.0009538714,0.0003593549,0.0002324495,0.00008770115,0.002529494,0.0007043959,0.00003495508,0.0009996439],"genre_scores_gemma":[0.9919983,0.0004535779,0.001019101,0.0005459347,0.000126767,0.003179964,0.001152448,0.00001100534,0.001512946],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004681725,"threshold_uncertainty_score":0.01566195,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07505917762754469,"score_gpt":0.3517412525875954,"score_spread":0.2766820749600507,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}